Delivery Order SPE2DB25D3504-SPE2DB25FVWMK
- Not listed
- The Defense Logistics Agency awarded a $2,601.43 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of FORTEO (fortified with 560 mcg/2.24 mL pen injections). The contract, which became effective on August 7, 2025, with an ultimate completion date of August 8, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its Conshohocken facility....
- The Defense Logistics Agency awarded a $12,869.67 delivery order to AmerisourceBergen Drug Corp for FORTEO (560 mcg/2.24 mL pen injections), a brand-name pharmaceutical product used in osteoporosis treatment. The contract is a firm fixed-price delivery order with an ultimate completion date of May 19, 2025, and was competitively awarded without set-aside provisions. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor for federal medical...
- The Defense Logistics Agency has awarded a $15,608.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of FORTEO (forteoide) 560 mcg/2.24 mL pen injections. The contract, awarded on May 30, 2025, with an ultimate completion date of June 2, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is a child contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,057.77 to AmerisourceBergen Drug Corp for the supply of FORTEO 560 MCG/2.24 ML pen injections on August 18, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,764.33 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of FORTEO 560 MCG/2.24 ML pen injections. This is a firm fixed-price delivery order with an ultimate completion date of August 15, 2025, and represents a non-set-aside competitive award. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under a larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $47,923.50 to AmerisourceBergen Drug Corp for the supply of FORTEO (560 mcg/2.24 mL pen injection), a pharmaceutical treatment for osteoporosis. The contract, awarded on April 21, 2025, with an ultimate completion date of April 22, 2025, was issued without a set-aside designation under a firm fixed price arrangement. Performance of this delivery order will take place at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $11,404.44 to AmerisourceBergen Drug Corp for the supply of FORTEO 560 MCG/2.24 ML pen injections on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a $6,492.02 delivery order to AmerisourceBergen Drug Corp for FORTEO (forteoide) 560 mcg/2.24 mL pen injections on September 8, 2025, with completion scheduled for September 9, 2025. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order to be performed at the vendor's corporate headquarters in Conshohocken, Pennsylvania. FORTEO is a prescription injectable medication commonly used in the treatment of osteoporosis...
- The Defense Logistics Agency awarded a $14,640.18 delivery order to AmerisourceBergen Drug Corp for FORTEO (560 mcg/2.24 mL pen injections) on April 24, 2025, with completion scheduled for April 25, 2025. This competitive award utilizes firm fixed pricing and is performed at the contractor's Conshohocken, Pennsylvania facility. The delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00...
- The Defense Logistics Agency awarded a $3,392.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of FORTEO (560 mcg/2.24 mL pen injections). This is a non-set-aside contract with an ultimate completion date of August 4, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. FORTEO is a prescription medication used primarily for treating osteoporosis in patients at high risk for fractures. This delivery order is...
- SPE2DB25D3504Indefinite Delivery Contract
- SPE2DB25D3504-SPE2DB25FVWMKDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,711.38 to AmerisourceBergen Drug Corp for the supply of FORTEO (560 mcg/2.24 ml pen injections). This non-set-aside, firm fixed-price delivery order was issued on September 26, 2025, with an ultimate completion date of September 29, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal medical procurement vendor supporting military and veteran healthcare systems. FORTEO is a prescription medication used primarily for osteoporosis treatment. Through its DLA prime contract, AmerisourceBergen supplies a broad portfolio of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains. The company's competitively awarded federal contracts demonstrate its capability to fulfill diverse federal medical supply requirements at varying order values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 9/26/25 |